Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. - Wikidata - awgldk - TriplyDB

Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.

Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.

http://www.wikidata.org/entity/Q34181738

about

Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.Vesicular integrity in Parkinson's disease Cellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cells Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance.Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.Dysautonomia in Parkinson disease Synergistic effects on dopamine cell death in a Drosophila model of chronic toxin exposure.Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screening Non-motor and motor features in LRRK2 transgenic mice.Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.Supplementation of Korean Red Ginseng improves behavior deviations in animal models of autism Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress Mitochondrial aldehyde dehydrogenase-2 activation prevents β-amyloid-induced endothelial cell dysfunction and restores angiogenesis.Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.Reduced aldehyde dehydrogenase expression in preeclamptic decidual mesenchymal stem/stromal cells is restored by aldehyde dehydrogenase agonists.Neurochemical and motor changes in mice with combined mutations linked to Parkinson's disease.Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease.Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.The vesicular monoamine transporter 2: an underexplored pharmacological target.Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.4-Hydroxy-trans-2-nonenal (4-HNE) induces neuronal SH-SY5Y cell death via hampering ATP binding at kinase domain of Akt1.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.Molecular Programming of Mesodiencephalic Dopaminergic Neuronal Subsets.Disruption of the Aldehyde Dehydrogenase 2 Gene Results in No Increase in Trabecular Bone Mass Due to Skeletal Loading in Association with Impaired Cell Cycle Regulation Through p21 Expression in the Bone Marrow Cells of Mice.Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.Inhibition of ALDH2 expression aggravates renal injury in a rat sepsis syndrome model

P2860

Q24632904-703EF8B4-8564-4EBE-9AB6-9A1F39F462DC Q26799354-E2396760-3F44-4D01-AD93-258C5F656F93 Q26826093-24F8963A-AD04-4490-B4EF-31E0DB8069CB Q26850502-37517AF6-50DB-48F8-91F3-C6787E41C1C8 Q27304699-32FDB7DE-F3DF-41E5-9C13-BC8C39D2E72A Q28385737-DF1DB448-07EB-4B3A-B0DB-BAE9409B161F Q28387863-86598D36-153F-4D93-B0C9-43620029BB7F Q30581658-85E4A3DF-F303-4776-A2E2-CDD8F9EF6C41 Q33896138-9D020BE2-11EA-49A2-BEAD-87940A7B0F32 Q34065897-A0F7CB20-08CD-49E6-9C1F-3F905F63FE63 Q34153906-2DAB55DD-8AF5-4520-83FC-B65BEB2A7385 Q34395219-7EC9BBAE-B54A-4896-A883-251CFE62169B Q34463831-A348DDD6-BAF8-4740-84C8-C7C87007E5C1 Q34688764-796634C1-9157-4CEF-95A5-E3CDB9781A6A Q34906371-E83DDF3C-1D82-418B-9865-A15C900AD875 Q34922393-8505F35C-0265-4EED-ADD8-AF25540DE247 Q35557892-DB66DD1C-7242-4AF8-B754-A21A194304E9 Q35619842-6850DA4C-D1E2-49D0-9E15-6B039B186DED Q36272936-F43AA2D1-58CE-4E39-A438-1D23117A3A57 Q36445937-F3E77095-D7FC-40CF-AA28-A9C84C74650B Q36534179-FD98279F-AC70-4987-820A-08A07E0A7090 Q36767908-9DF42F4C-2F39-4D10-AF1A-A529A3BC629E Q36882858-56496465-2F9B-4E94-B753-E4C4CBD815B5 Q36992085-8CAD36C0-956F-4367-8AA4-FA72EB7721CD Q37584540-E4967DC9-D639-4F59-AEE7-FDF72F7716D4 Q37638211-0ECCD949-C670-476A-A295-D54668D13317 Q37669523-3B22EAE6-35DC-4839-993F-D0AC3E24F1F4 Q38071648-B2F8A72C-52CE-4A36-A0BA-3F368CBE608C Q38124378-27CA2A82-CF7A-4C79-B1C8-93A65EF74AB1 Q38176494-C2A8C4C3-5F34-429C-B63F-53ECF81BB63F Q38258298-D504CE5B-F566-4ADE-9D61-458E432F765B Q38926644-50F4E7AD-F773-4485-B8C3-E0BF969A2AEA Q38995233-332A137B-1083-4923-A2D2-94AE32ABED1D Q39199926-FB1D8BCA-E06B-47BE-AD60-EAF193AA2D1F Q39294770-3B79C11A-17BB-480D-A7E0-5D43C3D0DB38 Q39300158-25F8F4EF-DE95-4960-A8D7-DF72970E92B7 Q41050801-38941981-7121-4A88-8B50-1C39EDC6D0D5 Q41261349-7154B72D-9CDC-4C1F-8CB0-B351D661853C Q41655727-32A957A4-0B45-4EF5-A840-BC0F5443F598 Q41672296-5AC58F35-00C4-4C67-A2A7-D70A90071E8D

P2860

Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.

http://www.wikidata.org/entity/Q34181738

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@ast

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@en

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@nl

type

label

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@ast

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@en

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@nl

prefLabel

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@ast

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@en

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@nl

P1433

Q34181738-FB57FCED-9DCE-4DBE-890E-398C7C9C22EE

P1476

Q34181738-D88F6C2A-DEEF-4B81-B74B-E4898E2157E2

P2093

Q34181738-0D276666-B936-4171-A8D9-4798688B251C

Q34181738-C04350F5-B818-4180-BBB7-F41B06A9539A

Q34181738-C35CB8F0-3D2D-4097-9459-315BD1ABDD2E

Q34181738-D4CDA3F8-9F3C-4742-807A-C0B5E7C1C4F8

Q34181738-D757D863-D302-40C4-A4F9-2F93B5AE9078

Q34181738-E4301E05-82CB-425D-BC5D-E036A0135FE3

P2860

Q34181738-007DD2EA-5D9C-4DC9-8299-585C1DB832B1

Q34181738-01D1C058-8B12-4C95-84F7-05FBE45034F4

Q34181738-04ACD52B-5CF6-4E68-9FE4-681808B0D673

Q34181738-04CC0579-0939-4D06-9CEA-3BA92F4406C4

Q34181738-11BAA996-F767-44D1-A603-630A79C79D5E

Q34181738-133CD4A4-D5ED-4D63-B54F-5581AE6EEC83

Q34181738-13D45F93-E796-4E86-A31D-675B575D20B9

Q34181738-17D4F11B-10C8-4E55-92DC-078F91F09F8A

Q34181738-1A042277-ADD7-463A-A881-71132DF67B66

Q34181738-1CCE818F-4EE8-4405-AF20-E5B6FAAFF960

P304

Q34181738-920615F1-051C-4F7A-8232-8C730C16BC53

P31

Q34181738-78D5F91E-1203-407F-BB25-2D97893A3785

P356

Q34181738-EEFF19AC-0C26-4519-BB38-5A8DA7209384

P407

Q34181738-C995E6D4-8FF6-4CF4-8214-8C4BE021990C

P433

Q34181738-7A9C59E4-2CFC-4129-8360-6F2074ED2C1E

P478

Q34181738-450E6471-AAB9-439A-82BE-240A592FC60E

P577

Q34181738-14873BBA-C7A8-45F8-91C9-6C65C5FC81E1

P5875

Q34181738-17E357C5-6AFE-41E1-9D35-EEE72BE4E057

P698

Q34181738-0B0BCF27-77DF-4914-8FD9-00018FBE8763

P921

Q34181738-825A8950-A837-4793-90BC-721C83312E07

P932

Q34181738-ED2B8308-8F32-43FE-839A-24DC4AABD8AD

P356

JOURNAL.PONE.0031522

P1433

P1476

Neurodegeneration and motor dy ...... tions for Parkinson's disease.

@en

P2093

David S Goldstein

http://www.w3.org/2001/XMLSchema#string

Elizabeth Fernandez

http://www.w3.org/2001/XMLSchema#string

Margaret Chia-Ying Wey

http://www.w3.org/2001/XMLSchema#string

Patricia Sullivan

http://www.w3.org/2001/XMLSchema#string

Paul Anthony Martinez

http://www.w3.org/2001/XMLSchema#string

Randy Strong

http://www.w3.org/2001/XMLSchema#string

P2860

Gait dynamics in mouse models of Parkinson's disease and Huntington's disease.

Alpha-synuclein in Lewy bodies

Monoamine metabolism and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice.

Expression and activities of aldo-keto oxidoreductases in Alzheimer disease

Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease.

Dose translation from animal to human studies revisited

D1/D2 dopamine receptor stimulation by L-dopa. A [14C]-2-deoxyglucose autoradiographic study.

Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.

Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.

L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network

P304

e31522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0031522

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221882632

http://www.w3.org/2001/XMLSchema#string

P698

22384032

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3284575

http://www.w3.org/2001/XMLSchema#string